

Testosterone undecanoate combined with depomedroxyprogesterone acetate in two month intervals in Asian men

Submission date 22/03/2004	Recruitment status Stopped	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 01/04/2004	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 20/08/2008	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Kirsten Vogelsong

Contact details

World Health Organization
20 Avenue Appia
Geneva
Switzerland
CH-1211
vogelsongk@who.int

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

WHO/HRP ID A15242

Study information

Scientific Title

Study objectives

To assess the efficacy of 500 mg Testosterone Undecanoate (TU) in combination with either 150 or 250 mg Depomedroxyprogesterone Acetate (DMPA) in suppression of sperm production, while maintaining adequate testosterone levels in fertile Asian men.

Due to funding limitations and focus on an alternative intervention, the study was never initiated and has been withdrawn from the World Health Organization (WHO) directory.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Male contraception

Interventions

1. 500 mg TU and 150 mg DMPA injected at eight week intervals (n = up to 32)
2. 500 mg TU and 250 mg DMPA injected at eight week intervals (n = up to 32)

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Testosterone undecanoate (TU), depomedroxyprogesterone acetate (DMPA)

Primary outcome measure

1. Changes in sperm concentrations to azoospermia or severe oligozoospermia at 24 weeks
2. Time to suppress spermatogenesis at 24 weeks

Secondary outcome measures

Suppression of gonadotropins and maintenance of normal blood testosterone levels at 24 weeks.

Overall study start date

01/06/2003

Completion date

01/06/2004

Reason abandoned (if study stopped)

Due to funding limitations and focus on an alternative intervention, the study was never initiated and has been withdrawn from the World Health Organization (WHO) directory.

Eligibility

Key inclusion criteria

1. Men in good health, aged 20 to 45
2. No desire for children for next 15 months
3. Normal reproductive state:
 - a. sperm concentrations greater than or equal to 20 million/ml
 - b. sperm motility greater than 50% (rapid and slow progressive) or grade a greater than 15%
 - c. morphology greater than 15% normal forms using the World Health Organisation (WHO) strict criteria, or
 - d. within the normal range for the centre
4. Body mass index between 20 and 29 kg/m²

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

64

Key exclusion criteria

No exclusion criteria

Date of first enrolment

01/06/2003

Date of final enrolment

01/06/2004

Locations

Countries of recruitment

China

India

Indonesia

Switzerland

Study participating centre

World Health Organization

Geneva

Switzerland

CH-1211

Sponsor information

Organisation

UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction

Sponsor details

World Health Organization

20 Avenue Appia

Geneva

Switzerland

CH-1211

Sponsor type

Research organisation

Website

<http://www.who.int/reproductive-health/hrp/>

ROR

<https://ror.org/01f80g185>

Funder(s)

Funder type

Research organisation

Funder Name

United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)
/World Health Organization (WHO)/World Bank - Special Programme of Research, Development
and Research Training in Human Reproduction (HRP)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration